← Back to headlines
Regeneron and Sanofi's Dupixent Receives Label Expansion for Allergic Fungal Rhinosinusitis
Regeneron and Sanofi have announced that their drug Dupixent has received a label expansion, allowing it to be used for the treatment of allergic fungal rhinosinusitis.
24 Feb, 15:32 — 24 Feb, 15:32
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Pfizer's Braftovi Receives Full FDA Approval for Colorectal Cancer
9m ago
Eight Confirmed Cases of Cereulide Intoxication from Contaminated Infant Milk in Belgium
21m ago
Alembic Pharma gets U.S. FDA nod for generic antifungal drug
22m ago
Study Suggests High-Altitude Living May Reduce Diabetes Risk
28m ago